Executives charged with R&D responsibilities within biotech and pharmaceutical organizations, both large and small, face myriad opportunities and challenges.
Drug development is a costly and risky business. The pharmaceutical industry is challenged by many factors related to discovering, researching, and developing new medicines. From translational research to the development of targeted therapies and personalized medicine to biotechnology to collaborations and outsourcing, opportunities abound. But at the same time, today’s R&D leaders face many challenges, including safety, productivity, long-term sustainability, new science, and managing global organizations.
This month’s Forum features the insights of these leaders as they discuss the opportunities and challenges they, and their organizations, face in the pursuit of researching and developing new therapies, as well as the challenges and lessons learned in leading their teams through a period of change…
Genomics and Clinical Trials
Strategies to Address Attrition
Sound Bites from the Field
Nancy A. Dreyer, Ph.D., Chief of Scientific Affairs Outcome. For more information, visit outcome.com.
Lisa Fell, VP of Recruitment Operations at MediciGroup Inc. For more information, visit patientrecruitment.com.
Martha R. Feller, Senior VP, Global Clinical Development – North America, at Kendle. For more information, visit kendle.com.
James C. Foster, President, CEO, and Chairman of Charles River Laboratories Inc. For more information, visit criver.com.
Suzanne Gagnon, M.D., Senior VP, Medical Affairs and Late Phase Services, Icon Clinical Research. For more information, visit iconclinical.com.
David Ginsberg, D.O., Chief Medical and Ethical Officer, Omnicare Clinical Research. For more information, visit omnicarecr.com.
Chris Jock, VP and General Manager, Kelly Scientific Resources. For more information, visit kellyscientific.us.
Stefanie Kuhner Sales Director, Acurian Inc. For more information, visit acurian.com.
Heather Mellon, Associate Director, Project Management, BioCor. For more information, visit biocor.com.
Mychelle Mowry, VP, Global Health Industries, Oracle Corp. For more information, visit oracle.com.
Monika Pietrek, M.D., Ph.D., Executive VP of Global Scientific and Medical Affairs, PRA International. For more information, visit praintl.com.
Stephen Raymond, Ph.D., Cofounder, Chief Scientific Officer and Quality Officer, PHT Corp. For more information, visit phtcorp.com.
Robert Sammis, Chief Operating Officer, etrials Worldwide Inc. For more information, visit etrials.com.
Ronny Schnel, Executive Director, Business Development and Client Services, Criterium Inc. For more information, visit criteriuminc.com.
Edward M. Sellers, M.D., Ph.D., President and CEO, Ventana Clinical Research Corp. For more information, visit ventana-crc.com.
Emma Sergeant, President, Clinical Trials Worldwide, Fast4wD Ogilvy. For more information, visit fast4wdogilvy.com.
Nancy Smerkanich, VP, Regulatory Affairs, Octagon Research Solutions Inc. For more information, visit octagonresearch.com.
Polina Voloshko, M.D., VP, Clinical Cardiovascular Services, Gentiae. For more information, visit gentiae.com.
John Watson, VP, Corporate Sales and Marketing, Covance Inc. For more information, visit covance.com.
Linda Wolf, member of the Media and Industry Public Relations Group, BBK Healthcare Inc. For more information, visit bbkhealthcare.com.
Martin Young, VP Services, North America, Phase Forward. For more information, visit phaseforward.com.
A Look at Late-Stage Development
The Productivity Crisis
Steve Arkinstall, Ph.D. VP of Research, United States, and Head of Research, Serono Research Institute, Serono Inc., Rockland, Mass.; Serono is a global biotech leader that is committed to discovering and developing medicines that address significant unmet medical needs. For more information, visit serono.com.
Lee E. Babiss, Ph.D. VP, Preclinical R&D, Roche, Nutley, N.J.; Roche is the U.S. prescription drug unit of the Roche Group, one of the world’s leading research- oriented healthcare groups. For more information, visit rocheusa.com.
VP and Global Head of Drug Safety Evaluation, Sanofi-Aventis, Bridgewater, N.J.; Sanofi-Aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine, and vaccines. For more information, visit sanofi-aventis.us.
Matt Coffey, Ph.D. Chief Scientific Officer, Oncolytics Biotech Inc., Calgary, Canada; Oncolytics Biotech is a biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. For more information, visit oncolyticsbiotech.com.
Carl M. Cohen, Ph.D. Chief Operating Officer, Biovest International Inc., Worcester, Mass; Biovest is dedicated to the development and commercialization of personalized cancer immunotherapies. For more information, visit biovest.com.
Oliver Fetzer, Ph.D. Senior VP, Corporate Development, Research and Development, Cubist Pharmaceuticals Inc., Lexington, Mass.; Cubist is a biopharmaceutical company focused on the research, development, and commercialization of products that address unmet medical needs in the acute-care environment. For more information, visit cubist.com.
Daniel Greenleaf. President and CEO, VioQuest Pharmaceuticals Inc., Basking Ridge, N.J.; VioQuest acquires, develops, and commercializes targeted late-preclinical and early-stage therapies with unique mechanisms of action for oncology, viral, and autoimmune disorders. For more information, visit vioquestpharm.com.
Michael S. Kinch, Ph.D. Senior Director, Oncology Research and Development, MedImmune Inc., Gaithersburg, Md.; MedImmune is a biotechnology company focused on the areas of infectious diseases, cancer, and inflammatory diseases. For more information, visit medimmune.com.
John Rothman, M.D. VP, Clinical Development, Advaxis Inc., North Brunswick, N.J.; Advaxis is a biotechnology company that is developing proprietary Listeria cancer vaccines. For more information, visit advaxis.com.
James Shannon, M.D. Head of Pharma Development, Novartis AG, Basel; Novartis researches, develops, manufactures, and markets innovative prescription drugs. For more information, visit novartis.com.
Catherine D. Strader, Ph.D. Executive VP, Discovery Research, Schering-Plough Research Institute, Kenilworth, N.J.; Schering-Plough Research Institute is the pharmaceutical research arm of Schering-Plough Corp., a global science-based healthcare company with leading prescription, consumer, and animal-health products. For more information, visit schering-plough.com.
Marc Tessier-Lavigne, Ph.D. Senior VP, Research Drug Discovery, Genentech Inc., South San Francisco, Calif.; Genentech discovers, develops, manufactures, and commercializes biotherapeutics for unmet medical needs. For more information, visit gene.com.
Mark Varney, Ph.D. Chief Operating Officer and Chief Scientific Officer, Cortex Pharmaceuticals Inc., Irvine, Calif.; Cortex focuses on novel drug therapies for neurological and psychiatric disorders. For more information, visit cortexpharm.com.
Frank Walsh, Ph.D. Executive VP, Head of Wyeth Discovery Research, Wyeth Pharmaceuticals, Madison, N.J.; Wyeth is one of the world’s largest research-driven pharmaceutical and healthcare products companies. For more information, visit wyeth.com.